Edwards Lifesciences (NYSE:EW) Releases Q2 2026 Earnings Guidance

robot
Abstract generation in progress

Edwards Lifesciences (NYSE:EW) has updated its Q2 2026 earnings guidance, projecting EPS between $0.700 and $0.760 and revenue of $1.7 billion, while also raising its full-year 2026 EPS guidance to $2.95-$3.05. Despite the positive guidance, the stock traded down to $79.69, and company insiders have sold over $7 million worth of shares in the past 90 days. Analysts currently maintain a “Moderate Buy” rating for the stock with an average price target of $95.74.

EW0.01%
IN-4.68%
RATING-3.89%
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned